X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PIRAMAL ENTERPRISES GSK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 60.1 37.6 159.8% View Chart
P/BV x 11.8 3.7 314.6% View Chart
Dividend Yield % 2.1 0.6 322.5%  

Financials

 GSK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-16
GSK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3,8501,065 361.5%   
Low Rs2,966805 368.4%   
Sales per share (Unadj.) Rs332.3383.0 86.8%  
Earnings per share (Unadj.) Rs44.355.1 80.4%  
Cash flow per share (Unadj.) Rs47.274.1 63.8%  
Dividends per share (Unadj.) Rs50.0017.50 285.7%  
Dividend yield (eoy) %1.51.9 78.4%  
Book value per share (Unadj.) Rs202.7719.9 28.2%  
Shares outstanding (eoy) m84.70172.56 49.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.32.4 420.1%   
Avg P/E ratio x76.917.0 453.3%  
P/CF ratio (eoy) x72.212.6 571.6%  
Price / Book Value ratio x16.81.3 1,294.2%  
Dividend payout %112.931.8 355.3%   
Avg Mkt Cap Rs m288,643161,344 178.9%   
No. of employees `0004.63.8 121.9%   
Total wages/salary Rs m4,43416,898 26.2%   
Avg. sales/employee Rs Th6,104.517,472.6 34.9%   
Avg. wages/employee Rs Th961.64,466.9 21.5%   
Avg. net profit/employee Rs Th813.72,512.8 32.4%   
INCOME DATA
Net Sales Rs m28,14866,099 42.6%  
Other income Rs m1,2182,425 50.2%   
Total revenues Rs m29,36668,524 42.9%   
Gross profit Rs m4,77418,723 25.5%  
Depreciation Rs m2483,274 7.6%   
Interest Rs m09,388 0.0%   
Profit before tax Rs m5,7448,485 67.7%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m26457 5.7%   
Tax Rs m2,0181,032 195.6%   
Profit after tax Rs m3,7529,506 39.5%  
Gross profit margin %17.028.3 59.9%  
Effective tax rate %35.112.2 288.9%   
Net profit margin %13.314.4 92.7%  
BALANCE SHEET DATA
Current assets Rs m21,46247,488 45.2%   
Current liabilities Rs m10,536104,362 10.1%   
Net working cap to sales %38.8-86.0 -45.1%  
Current ratio x2.00.5 447.6%  
Inventory Days Days6841 166.6%  
Debtors Days Days1651 32.1%  
Net fixed assets Rs m4,71726,532 17.8%   
Share capital Rs m847345 245.4%   
"Free" reserves Rs m16,308114,024 14.3%   
Net worth Rs m17,171124,221 13.8%   
Long term debt Rs m1675,812 0.0%   
Total assets Rs m30,620308,356 9.9%  
Interest coverage xNM1.9-  
Debt to equity ratio x00.6 0.2%  
Sales to assets ratio x0.90.2 428.9%   
Return on assets %12.36.1 200.0%  
Return on equity %21.97.7 285.5%  
Return on capital %33.610.0 337.0%  
Exports to sales %017.2 0.1%   
Imports to sales %15.16.6 228.0%   
Exports (fob) Rs m411,362 0.0%   
Imports (cif) Rs m4,2374,364 97.1%   
Fx inflow Rs m51914,435 3.6%   
Fx outflow Rs m8,3205,183 160.5%   
Net fx Rs m-7,8019,253 -84.3%   
CASH FLOW
From Operations Rs m1,386-67,773 -2.0%  
From Investments Rs m5,010-8,768 -57.1%  
From Financial Activity Rs m-6,38376,199 -8.4%  
Net Cashflow Rs m12-342 -3.4%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.0 255.0%  
FIIs % 23.8 26.6 89.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 16.5 93.3%  
Shareholders   102,036 93,274 109.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  AUROBINDO PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS